Common Stocks - 99.1%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 91.7%
|
|||
Biotechnology - 91.7%
|
|||
4D Molecular Therapeutics, Inc. (a)
|
31,000
|
743,070
|
|
AbbVie, Inc.
|
3,334,399
|
537,638,498
|
|
Absci Corp. (a)(b)
|
223,200
|
939,672
|
|
AC Immune SA (a)(b)
|
27,202
|
126,489
|
|
Acelyrin, Inc.
|
154,662
|
637,207
|
|
Adverum Biotechnologies, Inc. (a)
|
647,887
|
5,131,265
|
|
Aerovate Therapeutics, Inc. (a)
|
209,976
|
3,664,081
|
|
Alector, Inc. (a)(b)
|
3,535,753
|
17,395,905
|
|
Allena Pharmaceuticals, Inc. (a)(c)
|
93,683
|
1
|
|
Allogene Therapeutics, Inc. (a)(b)
|
2,875,777
|
7,189,443
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
692,370
|
102,768,479
|
|
ALX Oncology Holdings, Inc. (a)
|
939,049
|
9,982,091
|
|
Amgen, Inc.
|
1,272,550
|
389,209,418
|
|
Amicus Therapeutics, Inc. (a)
|
405,629
|
3,975,164
|
|
AnaptysBio, Inc. (a)
|
195,378
|
4,677,349
|
|
Annexon, Inc. (a)
|
308,844
|
1,491,717
|
|
Apellis Pharmaceuticals, Inc. (a)
|
1,283,379
|
50,372,626
|
|
Apogee Therapeutics, Inc.
|
392,132
|
17,896,904
|
|
Arcellx, Inc. (a)
|
1,269,090
|
65,992,680
|
|
Arcturus Therapeutics Holdings, Inc. (a)(b)
|
589,430
|
22,875,778
|
|
Arcus Biosciences, Inc. (a)(b)
|
2,394,962
|
36,092,077
|
|
Argenx SE ADR (a)
|
113,406
|
42,075,894
|
|
ArriVent Biopharma, Inc. (b)(d)
|
1,798,400
|
34,906,944
|
|
Arrowhead Pharmaceuticals, Inc. (a)
|
713,170
|
16,367,252
|
|
Ars Pharmaceuticals, Inc. (a)(b)
|
1,082,956
|
9,616,649
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
659,409
|
89,086,156
|
|
Astria Therapeutics, Inc. (a)
|
413,156
|
3,912,587
|
|
Astria Therapeutics, Inc. warrants (a)
|
115,136
|
551,327
|
|
aTyr Pharma, Inc. (a)
|
2,258,063
|
3,906,449
|
|
Aura Biosciences, Inc. (a)(b)
|
229,592
|
1,687,501
|
|
Autolus Therapeutics PLC ADR (a)
|
454,133
|
1,902,817
|
|
Avidity Biosciences, Inc. (a)
|
833,702
|
22,393,236
|
|
AVROBIO, Inc. (c)(e)(f)
|
403,256
|
5,000,003
|
|
Axcella Health, Inc. (a)(c)
|
66,454
|
1
|
|
Beam Therapeutics, Inc. (a)(b)
|
528,150
|
12,580,533
|
|
BeiGene Ltd. ADR (a)
|
9,198
|
1,369,122
|
|
BeyondSpring, Inc. (a)(b)
|
464,467
|
1,221,548
|
|
BioCryst Pharmaceuticals, Inc. (a)(b)
|
1,787,181
|
11,545,189
|
|
Biogen, Inc. (a)
|
122,311
|
27,512,636
|
|
Biohaven Ltd. (a)(b)
|
1,812,012
|
63,601,621
|
|
Biomea Fusion, Inc. (a)(b)
|
392,129
|
4,125,197
|
|
BioXcel Therapeutics, Inc. (a)(b)
|
8,945
|
16,190
|
|
Blueprint Medicines Corp. (a)
|
639,952
|
67,553,333
|
|
Boundless Bio, Inc. (b)
|
23,700
|
216,144
|
|
BridgeBio Pharma, Inc. (f)
|
733,408
|
20,542,758
|
|
BridgeBio Pharma, Inc. (a)
|
688,696
|
19,290,375
|
|
Cargo Therapeutics, Inc.
|
236,900
|
4,501,100
|
|
Cartesian Therapeutics, Inc. (b)
|
509,159
|
17,678,000
|
|
Cartesian Therapeutics, Inc. rights (a)(c)
|
5,385,728
|
754,002
|
|
Celldex Therapeutics, Inc. (a)
|
829,064
|
27,607,831
|
|
Centessa Pharmaceuticals PLC ADR (a)(b)
|
2,787,194
|
24,053,484
|
|
Chinook Therapeutics, Inc. rights (a)(c)
|
115,821
|
1
|
|
Codiak Biosciences, Inc. (a)(b)(c)
|
448,539
|
4
|
|
Codiak Biosciences, Inc. warrants 9/15/27 (a)(c)
|
46,000
|
0
|
|
Cogent Biosciences, Inc. (a)
|
1,126,094
|
9,020,013
|
|
Crinetics Pharmaceuticals, Inc. (a)
|
1,115,050
|
49,519,371
|
|
CRISPR Therapeutics AG (a)(b)
|
202,007
|
10,855,856
|
|
Cyclerion Therapeutics, Inc. (a)
|
41,864
|
111,777
|
|
Cyclerion Therapeutics, Inc. (a)(f)
|
4,740
|
12,656
|
|
Cytokinetics, Inc. (a)
|
381,052
|
18,484,833
|
|
Day One Biopharmaceuticals, Inc. (a)
|
909,332
|
12,066,836
|
|
Denali Therapeutics, Inc. (a)
|
200,069
|
3,713,281
|
|
Dianthus Therapeutics, Inc. (a)
|
236,393
|
5,108,453
|
|
Disc Medicine, Inc. (a)(b)
|
403,920
|
13,713,084
|
|
Disc Medicine, Inc. rights (a)(c)
|
1,555,907
|
16
|
|
Dyne Therapeutics, Inc. (a)
|
599,750
|
19,120,030
|
|
Entrada Therapeutics, Inc. (a)(b)
|
150,853
|
2,333,696
|
|
Exelixis, Inc. (a)
|
179,454
|
3,892,357
|
|
Foghorn Therapeutics, Inc. (a)(b)
|
907,441
|
5,290,381
|
|
Geron Corp. (a)
|
5,175,382
|
18,372,606
|
|
Geron Corp. warrants 12/31/25 (a)
|
2,100,000
|
2,226,000
|
|
Gilead Sciences, Inc.
|
1,393,204
|
89,541,221
|
|
Gossamer Bio, Inc. (a)(b)
|
7,914,394
|
4,669,492
|
|
Gritstone Bio, Inc. (a)(b)
|
1,285,109
|
994,289
|
|
Gritstone Bio, Inc. warrants (a)(c)
|
1,333,333
|
13
|
|
Ideaya Biosciences, Inc. (a)
|
1,050,257
|
38,386,893
|
|
Idorsia Ltd. (a)(b)
|
3,039,242
|
8,657,786
|
|
IGM Biosciences, Inc. (a)(b)
|
859,982
|
7,163,650
|
|
Immunocore Holdings PLC ADR (a)(b)
|
207,718
|
10,174,028
|
|
Immunome, Inc. (a)(b)
|
483,882
|
7,229,197
|
|
Immunovant, Inc. (a)
|
789,121
|
20,035,782
|
|
Inozyme Pharma, Inc. (a)(b)
|
2,471,087
|
11,910,639
|
|
Insmed, Inc. (a)
|
1,015,219
|
55,887,806
|
|
Intellia Therapeutics, Inc. (a)(b)
|
823,501
|
17,606,451
|
|
IO Biotech, Inc. (a)
|
314,600
|
374,374
|
|
Ionis Pharmaceuticals, Inc. (a)
|
830,577
|
31,204,778
|
|
Janux Therapeutics, Inc. (a)
|
366,399
|
19,602,347
|
|
Keros Therapeutics, Inc. (a)
|
388,529
|
18,210,354
|
|
Korro Bio, Inc. (f)
|
32,866
|
1,686,026
|
|
Korro Bio, Inc. (a)(b)
|
92,276
|
4,733,759
|
|
Krystal Biotech, Inc. (a)(d)
|
1,912,422
|
306,083,141
|
|
Kymera Therapeutics, Inc. (a)(b)
|
456,141
|
14,646,688
|
|
Legend Biotech Corp. ADR (a)
|
600,210
|
24,014,402
|
|
Lexicon Pharmaceuticals, Inc. (f)
|
4,608,300
|
7,834,110
|
|
Lexicon Pharmaceuticals, Inc. (a)(b)
|
167,910
|
285,447
|
|
Madrigal Pharmaceuticals, Inc. (a)(b)
|
91,124
|
21,519,844
|
|
MannKind Corp. (a)(b)
|
4,406,401
|
20,577,893
|
|
Merus BV (a)(b)
|
1,194,770
|
63,609,555
|
|
Moderna, Inc. (a)
|
759,751
|
108,302,505
|
|
Monte Rosa Therapeutics, Inc. (a)
|
1,082,720
|
4,460,806
|
|
Moonlake Immunotherapeutics Class A (a)(b)
|
179,741
|
7,308,269
|
|
Morphic Holding, Inc. (a)(b)
|
1,019,499
|
30,962,185
|
|
Natera, Inc. (a)
|
357,132
|
38,045,272
|
|
Nurix Therapeutics, Inc. (a)
|
13,046
|
205,475
|
|
Nuvalent, Inc. Class A (a)
|
234,474
|
15,386,184
|
|
Omega Therapeutics, Inc. (a)(b)
|
245,003
|
485,106
|
|
ORIC Pharmaceuticals, Inc. (a)
|
117,400
|
1,055,426
|
|
PepGen, Inc. (a)
|
387,728
|
6,331,598
|
|
Poseida Therapeutics, Inc. (a)
|
223,383
|
667,915
|
|
Praxis Precision Medicines, Inc. (a)
|
343,977
|
16,325,148
|
|
Protagonist Therapeutics, Inc. (a)
|
423,913
|
11,933,151
|
|
Prothena Corp. PLC (a)(b)
|
738,117
|
15,360,215
|
|
PTC Therapeutics, Inc. (a)
|
670,611
|
24,383,416
|
|
Rallybio Corp. (a)(b)
|
581,092
|
970,424
|
|
RAPT Therapeutics, Inc. (a)
|
802,700
|
3,218,827
|
|
Recursion Pharmaceuticals, Inc. Class A (a)(b)
|
149,900
|
1,241,172
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
219,383
|
215,030,441
|
|
Regulus Therapeutics, Inc. (a)(b)
|
2,922,600
|
6,692,754
|
|
Replimune Group, Inc. (a)(b)
|
420,215
|
2,214,533
|
|
Revolution Medicines, Inc. (a)
|
618,698
|
23,714,694
|
|
Rhythm Pharmaceuticals, Inc. (a)(b)
|
15,603
|
556,715
|
|
Rocket Pharmaceuticals, Inc. (a)
|
532,936
|
11,362,196
|
|
Roivant Sciences Ltd. (a)(b)
|
3,422,619
|
35,458,333
|
|
Sage Therapeutics, Inc. (a)
|
1,259,552
|
13,993,623
|
|
Sana Biotechnology, Inc. (a)(b)
|
466,094
|
3,495,705
|
|
Sarepta Therapeutics, Inc. (a)
|
390,299
|
50,684,228
|
|
Scholar Rock Holding Corp. (a)(b)
|
1,632,599
|
15,330,105
|
|
Scholar Rock Holding Corp. warrants 12/31/25 (a)(f)
|
17,850
|
63,166
|
|
Sensorion SA (a)(d)
|
20,279,025
|
16,895,994
|
|
Seres Therapeutics, Inc. (a)(b)
|
854,347
|
854,347
|
|
Shattuck Labs, Inc. (a)
|
481,542
|
3,553,780
|
|
SpringWorks Therapeutics, Inc. (a)
|
492,509
|
20,419,423
|
|
Spyre Therapeutics, Inc. (a)
|
261,553
|
9,141,277
|
|
Stoke Therapeutics, Inc. (a)(b)
|
392,470
|
5,737,911
|
|
Summit Therapeutics, Inc. (a)(b)
|
4,488,329
|
38,981,137
|
|
Tango Therapeutics, Inc. (f)
|
466,637
|
3,229,128
|
|
Tango Therapeutics, Inc. (a)
|
310,288
|
2,147,193
|
|
Taysha Gene Therapies, Inc. (a)
|
7,692,583
|
26,385,560
|
|
Tenaya Therapeutics, Inc. (a)(b)
|
1,655,313
|
6,968,868
|
|
TG Therapeutics, Inc. (a)(b)
|
1,197,220
|
19,514,686
|
|
Twist Bioscience Corp. (a)(b)
|
166,525
|
6,977,398
|
|
Tyra Biosciences, Inc. (a)
|
76,100
|
1,234,342
|
|
Tyra Biosciences, Inc. (f)
|
115,296
|
1,870,101
|
|
Ultragenyx Pharmaceutical, Inc. (a)
|
726,130
|
29,146,858
|
|
United Therapeutics Corp. (a)
|
163,393
|
44,954,316
|
|
Vaxcyte, Inc. (a)
|
900,480
|
63,276,730
|
|
Vera Therapeutics, Inc. (a)
|
441,778
|
16,783,146
|
|
Vertex Pharmaceuticals, Inc. (a)
|
387,709
|
176,539,416
|
|
Viking Therapeutics, Inc. (a)
|
439,952
|
27,391,412
|
|
Viridian Therapeutics, Inc. (a)
|
1,005,738
|
12,018,569
|
|
Vor Biopharma, Inc. (a)(b)
|
955,917
|
1,290,488
|
|
Xenon Pharmaceuticals, Inc. (a)
|
539,634
|
20,543,866
|
|
Zealand Pharma A/S (a)
|
743,030
|
69,706,090
|
|
Zentalis Pharmaceuticals, Inc. (a)(b)
|
562,933
|
6,687,644
|
|
4,092,346,276
|
|||
Consumer Staples Distribution & Retail - 0.0%
|
|||
Drug Retail - 0.0%
|
|||
MedAvail Holdings, Inc. (a)
|
55
|
0
|
|
Financial Services - 0.9%
|
|||
Diversified Financial Services - 0.9%
|
|||
Bio AB Holdings LLC (c)(f)
|
1,954,526
|
36,881,906
|
|
Health Care Equipment & Supplies - 0.0%
|
|||
Health Care Equipment - 0.0%
|
|||
Aradigm Corp. (a)(c)
|
148,009
|
1
|
|
Aradigm Corp. (a)(c)
|
11,945
|
0
|
|
Glaukos Corp. (a)
|
5,700
|
642,504
|
|
Novocure Ltd. (a)
|
11,113
|
244,597
|
|
887,102
|
|||
Health Care Technology - 0.2%
|
|||
Health Care Technology - 0.2%
|
|||
Schrodinger, Inc. (a)(b)
|
398,001
|
8,564,982
|
|
Life Sciences Tools & Services - 0.1%
|
|||
Life Sciences Tools & Services - 0.1%
|
|||
10X Genomics, Inc. (a)
|
172,200
|
3,860,724
|
|
Pharmaceuticals - 6.2%
|
|||
Pharmaceuticals - 6.2%
|
|||
Adimab LLC (a)(c)(f)(g)
|
1,954,526
|
10,554,440
|
|
Afferent Pharmaceuticals, Inc. rights 12/31/24 (a)(c)
|
8,274,568
|
1,654,914
|
|
Alto Neuroscience, Inc. (b)
|
168,700
|
2,017,652
|
|
Arvinas Holding Co. LLC (a)
|
296,816
|
9,836,482
|
|
Atea Pharmaceuticals, Inc. (a)
|
958,300
|
3,516,961
|
|
Axsome Therapeutics, Inc. (a)(b)
|
137,403
|
10,089,502
|
|
Contineum Therapeutics, Inc. Class A
|
58,800
|
900,816
|
|
Corcept Therapeutics, Inc. (a)(b)
|
822,199
|
24,805,744
|
|
Edgewise Therapeutics, Inc. (a)
|
474,685
|
8,131,354
|
|
Enliven Therapeutics, Inc. (a)
|
500,038
|
11,285,858
|
|
Fulcrum Therapeutics, Inc. (a)
|
1,255,055
|
9,852,182
|
|
Galderma Group AG
|
82,220
|
6,709,570
|
|
GH Research PLC (a)(b)
|
255,924
|
3,605,969
|
|
Harmony Biosciences Holdings, Inc. (a)
|
91,925
|
2,702,595
|
|
Indivior PLC (a)
|
71,500
|
1,323,943
|
|
Intra-Cellular Therapies, Inc. (a)
|
133,799
|
8,996,645
|
|
Longboard Pharmaceuticals, Inc. (a)(b)(d)
|
1,778,489
|
33,560,087
|
|
Novo Nordisk A/S Series B sponsored ADR
|
51,700
|
6,993,976
|
|
Nuvation Bio, Inc. Class A (a)(b)
|
3,123,214
|
9,681,963
|
|
OptiNose, Inc. (a)
|
449,131
|
485,061
|
|
OptiNose, Inc. warrants (a)
|
91,712
|
15,870
|
|
Pharvaris BV (a)
|
112,407
|
2,131,237
|
|
Pliant Therapeutics, Inc. (a)
|
37,431
|
454,038
|
|
Structure Therapeutics, Inc. ADR (a)
|
227,004
|
7,763,537
|
|
UCB SA
|
546,274
|
76,626,273
|
|
Ventyx Biosciences, Inc. (a)
|
295,300
|
1,411,534
|
|
Verona Pharma PLC ADR (a)
|
719,601
|
8,685,584
|
|
Verrica Pharmaceuticals, Inc. (a)(b)
|
1,108,069
|
9,429,667
|
|
WAVE Life Sciences (a)
|
660,911
|
4,084,430
|
|
277,307,884
|
|||
TOTAL COMMON STOCKS
(Cost $2,997,780,405)
|
4,419,848,874
|
||
Convertible Preferred Stocks - 0.9%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 0.8%
|
|||
Biotechnology - 0.8%
|
|||
ElevateBio LLC Series C (a)(c)(f)
|
216,600
|
662,796
|
|
National Resilience, Inc. Series B (a)(c)(f)
|
732,064
|
28,279,632
|
|
SalioGen Therapeutics, Inc. Series B (a)(c)(f)
|
94,461
|
6,315,662
|
|
35,258,090
|
|||
Health Care Providers & Services - 0.1%
|
|||
Health Care Services - 0.1%
|
|||
Scorpion Therapeutics, Inc. Series B (a)(c)(f)
|
3,099,905
|
7,191,780
|
|
Pharmaceuticals - 0.0%
|
|||
Pharmaceuticals - 0.0%
|
|||
Afferent Pharmaceuticals, Inc. Series C (a)(c)(f)
|
8,274,568
|
83
|
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $28,408,650)
|
42,449,953
|
||
Money Market Funds - 5.8%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 5.39% (h)
|
12,561,804
|
12,564,317
|
|
Fidelity Securities Lending Cash Central Fund 5.39% (h)(i)
|
246,906,088
|
246,930,778
|
|
TOTAL MONEY MARKET FUNDS
(Cost $259,474,244)
|
259,495,095
|
||
TOTAL INVESTMENT IN SECURITIES - 105.8%
(Cost $3,285,663,299)
|
4,721,793,922
|
NET OTHER ASSETS (LIABILITIES) - (5.8)%
|
(259,947,309)
|
NET ASSETS - 100.0%
|
4,461,846,613
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Level 3 security
|
(d)
|
Affiliated company
|
(e)
|
Security or a portion of the security purchased on a delayed delivery or when-issued basis.
|
(f)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $130,124,247 or 2.9% of net assets.
|
(g)
|
Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
|
(h)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(i)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Adimab LLC
|
9/17/14 - 6/05/15
|
7,898,551
|
Afferent Pharmaceuticals, Inc. Series C
|
7/01/15
|
0
|
AVROBIO, Inc.
|
1/30/24
|
5,000,003
|
Bio AB Holdings LLC
|
9/17/14 - 6/05/15
|
23,546,759
|
BridgeBio Pharma, Inc.
|
9/25/23
|
20,000,036
|
Cyclerion Therapeutics, Inc.
|
4/02/19
|
1,404,026
|
ElevateBio LLC Series C
|
3/09/21
|
908,637
|
Korro Bio, Inc.
|
7/14/23
|
1,854,573
|
Lexicon Pharmaceuticals, Inc.
|
3/11/24
|
10,000,011
|
National Resilience, Inc. Series B
|
12/01/20
|
9,999,994
|
SalioGen Therapeutics, Inc. Series B
|
12/10/21
|
10,000,019
|
Scholar Rock Holding Corp. warrants 12/31/25
|
6/17/22
|
0
|
Scorpion Therapeutics, Inc. Series B
|
1/08/21
|
7,500,000
|
Tango Therapeutics, Inc.
|
8/09/23
|
2,403,181
|
Tyra Biosciences, Inc.
|
2/02/24
|
1,500,001
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 5.39%
|
17,016,519
|
195,135,179
|
199,587,199
|
102,515
|
(182)
|
-
|
12,564,317
|
0.0%
|
Fidelity Securities Lending Cash Central Fund 5.39%
|
286,197,060
|
398,007,584
|
437,273,866
|
1,704,340
|
5,760
|
(5,760)
|
246,930,778
|
1.0%
|
Total
|
303,213,579
|
593,142,763
|
636,861,065
|
1,806,855
|
5,578
|
(5,760)
|
259,495,095
|
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
ArriVent Biopharma, Inc.
|
38,737,536
|
-
|
-
|
-
|
-
|
(3,830,592)
|
34,906,944
|
Cartesian Therapeutics, Inc.
|
8,198,668
|
2,823,722
|
-
|
-
|
-
|
6,655,610
|
-
|
Cartesian Therapeutics, Inc. rights
|
700,145
|
-
|
-
|
-
|
-
|
53,857
|
-
|
Krystal Biotech, Inc.
|
316,567,405
|
-
|
12,316,047
|
-
|
6,863,547
|
(5,031,764)
|
306,083,141
|
Longboard Pharmaceuticals, Inc.
|
39,446,886
|
-
|
-
|
-
|
-
|
(5,886,799)
|
33,560,087
|
Regulus Therapeutics, Inc.
|
4,296,222
|
-
|
-
|
-
|
-
|
2,396,532
|
-
|
Sensorion SA
|
5,544,514
|
10,014,758
|
-
|
-
|
-
|
1,336,722
|
16,895,994
|
Taysha Gene Therapies, Inc.
|
34,737,254
|
-
|
8,539,593
|
-
|
5,569,396
|
(5,381,498)
|
-
|
Total
|
448,228,630
|
12,838,480
|
20,855,640
|
-
|
12,432,943
|
(9,687,932)
|
391,446,166
|